Excellence In Breeding

JANE WILLIAMS | July 29, 2019 | 72 views

With the cost of sequencing rapidly declining, it seems inevitable that routine of genomic information in breeding programs in Africa and South Asia will become more prevalent. However, there are certain capabilities, tools, and technologies that need to be in place to be able to exploit this type of information effectively and use it to drive higher rates of genetic gains.

Spotlight

Akira

Akira is reimagining Canadian healthcare — we're changing how healthcare is delivered and empowering patients to be engaged and proactive about their health. Right Health combines virtual and face-to-face care to offer on-demand, accessible healthcare convenience at your fingertips. Akira is the technology platform within Right Health’s offering that provides you with an instant connection to great Canadian doctors, nurse practitioners, and more — all by secure text or video through the Akira smartphone app.

OTHER ARTICLES

Advancement in Genomics Accelerating its Penetration into Precision Health

Article | April 17, 2020

Genomics is an interdisciplinary field of biology emphasizing the structure, editing, evolution, function, and mapping of genomes. It is creating deeper inroads across the precision health domain with the increasing introduction of advanced technologies such as quantum simulation, next-generation sequencing (NGS), and precise genome manipulation. As precision health focuses on providing the proper intervention to the right patient at the right time, genomics increasingly finds applications in human and pathogen genome sequencing in clinical and research spaces. Rising Hereditary Diseases Burden Paving the Way for Genomics in Precision Health In the last few years, a significant surge in the prevalence of diseases and ailments such as diabetes, obesity, baldness, and others has been witnessed across the globe. A history of family members with chronic diseases, such as cancer, diabetes, high blood pressure, hearing issues, and heart disease, can sometimes continue into the next generation. Hence, the study of genes is extensively being conducted for predicting health risks and early treatment of these diseases. It also finds use in CRISPR-based diagnostics and the preparation of precision medication for the individual. In addition, ongoing advancements in genomics are making it possible to identify different genetic traits that persuade people to more widespread diseases and health problems. The Emergence of Genomics Improves Disease Understanding Genomics refers to the study of the complete genetic makeup of a cell or organism. Increasing scientific research in the area substantially contributes to increasing knowledge about the human genome and assists in improving the ability to understand disease etiology, risk, diagnosis, treatment, and prevention. On account of these improvements, innovative genomic technologies and tools are being developed to enable better precision health not only for the individual but for various regional populations as well. The Way Forward With growing preference for personalized medicine and an increasing need for more accurate pathogen detection and diagnostics, genomics is gaining huge popularity across the precision health domain. Also, increasing research activities for developing novel high-precision therapeutics and rising importance of gene study in the prevention, diagnosis, and management of infectious and genetic diseases will further pave the way for genomics in the forthcoming years.

Read More

Top 10 biotech IPOs in 2019

Article | September 13, 2019

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
DIAGNOSTICS

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | April 20, 2021

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | February 12, 2020

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Spotlight

Akira

Akira is reimagining Canadian healthcare — we're changing how healthcare is delivered and empowering patients to be engaged and proactive about their health. Right Health combines virtual and face-to-face care to offer on-demand, accessible healthcare convenience at your fingertips. Akira is the technology platform within Right Health’s offering that provides you with an instant connection to great Canadian doctors, nurse practitioners, and more — all by secure text or video through the Akira smartphone app.

Related News

Agricultural Biotechnology Market Size, Share, Analysis, Report and forecast to 2022

biotech | March 06, 2017

According to Stratistics MRC, the Global Agricultural Biotechnology market is accounted for $20.08 billion in 2015 and is expected to reach $39.5 billion by 2022 growing at a CAGR of 10.1% from 2015 to 2022. Factors stimulating the market growth are increasing demand for food, growing area of biotech crops, rising demand for biofuels & bio plastic production and demand for animal feed. Furthermore, increased investments and capital inflow for industry participants and research & development within Africa and Asia Pacific region will provide more growth prospects towards the market.

Read More

Agricultural biotechnology crucial for feeding world population

biotech | January 31, 2017

Sarnia - It took until 1800 for the world population to reach one billion people. The second billion was reached in only 130 years (1930), the third billion in less than 30 years (1959), the fourth billion in 15 years (1974) and the fifth billion in only 13 years (1987). During the 20th century alone, the global population grew from 1.6 billion to over six billion people.

Read More

Agricultural Biotechnology Market Size, Share, Analysis, Report and forecast to 2022

biotech | March 06, 2017

According to Stratistics MRC, the Global Agricultural Biotechnology market is accounted for $20.08 billion in 2015 and is expected to reach $39.5 billion by 2022 growing at a CAGR of 10.1% from 2015 to 2022. Factors stimulating the market growth are increasing demand for food, growing area of biotech crops, rising demand for biofuels & bio plastic production and demand for animal feed. Furthermore, increased investments and capital inflow for industry participants and research & development within Africa and Asia Pacific region will provide more growth prospects towards the market.

Read More

Agricultural biotechnology crucial for feeding world population

biotech | January 31, 2017

Sarnia - It took until 1800 for the world population to reach one billion people. The second billion was reached in only 130 years (1930), the third billion in less than 30 years (1959), the fourth billion in 15 years (1974) and the fifth billion in only 13 years (1987). During the 20th century alone, the global population grew from 1.6 billion to over six billion people.

Read More

Events